http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Naoki Iguchi,이혜은,윤원덕,김수암 한국해양과학기술원 2010 Ocean science journal Vol.45 No.2
This study investigated the sexual maturation process, release of spermatozoa or eggs and oocyte diameter of the rhizostomid medusae Nemopilema nomurai using samples collected from August 2006 to June 2008 from the waters around Korea and Japan, including peripheral areas outside the species’ usual habitat. Immature medusae were observed from June to October only in the western sector of the study area. The onset of spermatozoa and egg release occurred in September and October, respectively, and peaked in December and January. Medusae migrated eastward from source areas with the Tsushima Warm Current, where they formed gametes and spawned. Peak position and maximum oocyte diameter increased as the gonads developed according to the size-frequency distribution of oocytes. No fertilized eggs or embryos were found in the gonads. The correlation was analyzed with bell diameter, maximum oocyte diameter, sampling date, surface water temperature and gonad color to estimate which environmental factors and maturation indices were related to the maturation stage of females. Maturation stage correlated well with maximum oocyte diameter, which correlated negatively with surface water temperature. There was no significant correlation between bell diameter and maturation stage. Therefore, bell diameter was inappropriate for determining maturation index. Sex could not be distinguished clearly by gonad color. However, light pink gonads were more prevalent in males and various deep colors such as orange and brown were more frequent in female medusae.
Hideyuki Tamai,Naoki Shingaki,Yoshiyuki Mori,Kosaku Moribata,Akira Kawashima,Yoshimasa Maeda,Toru Niwa,Hisanobu Deguchi,Izumi Inoue,Takao Maekita,Mikitaka Iguchi,Jun Kato,Masao Ichinose 거트앤리버 소화기연관학회협의회 2016 Gut and Liver Vol.10 No.4
Background/Aims: This study aimed to predict sustained viral response (SVR) to low-dose pegylated interferon (PEGIFN) plus ribavirin of elderly and/or cirrhotic patients with genotype 2 hepatitis C virus (HCV) using viral response within 2 weeks. Methods: Low-dose PEG-IFN-α-2b plus ribavirin was administered to 50 elderly and/or cirrhotic patients with genotype 2 HCV for 24 weeks. The dynamics of HCV RNA and HCV core antigen levels within 2 weeks were measured. Results: The patients’ median age was 66 years. There were 21 male and 29 female patients. The median baseline HCV RNA level was 5.7 log IU/mL. Rapid viral response was achieved in 17 patients (34%), SVR in 28 (56%), and two (4%) discontinued treatment. Univariate analysis of factors contributing to SVR showed significant differences for sex, baseline virus level, and response within 4 weeks. When 40 fmol/L was set as the cutoff value for the core antigen level at 1 week, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for predicting SVR were 93%, 75%, 84%, 88%, and 85%, respectively. Conclusions: Low-dose PEG-IFN plus ribavirin was a safe and costeffective treatment for elderly and/or cirrhotic patients with genotype 2 HCV, and the viral response within 2 weeks was a useful predictor of SVR.
( Hideyuki Tamai ),( Yoshiyuki Ida ),( Akira Kawashima ),( Naoki Shingaki ),( Ryo Shimizu ),( Kosaku Moribata ),( Tetsushi Nasu ),( Takao Maekita ),( Mikitaka Iguchi ),( Jun Kato ),( Taisei Nakao ),( 대한간학회 2017 Gut and Liver Vol.11 No.4
Background/Aims: The present study aimed to evaluate the safety and efficacy of simeprevir-based triple therapy with reduced doses of pegylated interferon (PEG-IFN) and ribavirin for interferon (IFN) ineligible patients, such as elderly and/or cirrhotic patients, and to elucidate the factors contributing to a sustained virologic response (SVR). Methods: One hundred IFN ineligible patients infected with genotype 1b hepatitis C virus (HCV) were treated. Simeprevir (100 mg) was given orally together with reduced doses of PEG-IFN-α 2a (90 μg), and ribavirin (200 mg less than the recommended dose). Results: The patients` median age was 70 years, and 70 patients were cirrhotic. Three patients (3%) discontinued treatment due to adverse events. The SVR rate was 64%. Factors that significantly contributed to the SVR included the γ-glutamyl transferase and α-fetoprotein levels, interleukin- 28B (IL28B) polymorphism status, and the level and reduction of HCV RNA at weeks 2 and 4. The multivariate analysis showed that the IL28B polymorphism status was the only independent factor that predicted the SVR, with a positive predictive value of 77%. Conclusions: Simeprevir-based triple therapy with reduced doses of PEG-IFN and ribavirin was safe and effective for IFN ineligible patients infected with genotype 1b HCV. IL28B polymorphism status was a useful predictor of the SVR. (Gut Liver 2017;11:551-558)
The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients
( Shinya Taki ),( Hideyuki Tamai ),( Yoshiyuki Ida ),( Naoki Shingaki ),( Akira Kawashima ),( Ryo Shimizu ),( Kosaku Moribata ),( Takao Maekita ),( Mikitaka Iguchi ),( Jun Kato ),( Taisei Nakao ),( Ma 대한간학회 2018 Gut and Liver Vol.12 No.1
Background/Aims: Although daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged ≥75 years were excluded in the phase III trial. The present study aimed to evaluate the safety and efficacy of this therapy for elderly patients aged ≥75 years and to clarify whether an extremely high sustained virological response (SVR) rate can be achieved, even in a real-world setting when patients with resistance-associated substitutions (RASs) to nonstructural protein 5A (NS5A) inhibitors or prior simeprevir failure are excluded. Methods: Daclatasvir (60 mg) and asunaprevir (100 mg) were orally administered daily for 24 weeks. Patients without pre-existing NS5A RASs and simeprevir failure were enrolled in this study. Results: Overall, 110 patients were treated. The median age was 73 years old. The SVR rates of total patients, those aged ≥75 years, and those aged <75 years were 97% (107/110), 98% (46/47), and 97% (61/63), respectively. The treatment of two patients (2%) was discontinued because of adverse events. Conclusions: Daclatasvir with asunaprevir was a safe treatment, even in patients aged ≥75 years. When patients without pre-existing NS5A RASs and prior simeprevir failure were selected, an extremely high SVR rate could be achieved irrespective of age. (Gut Liver 2018;12:86-93)
Kawaguchi, So,Shiomoto, Akihiro,Imai, Keiri,Tsarina, Yoriko,Yamaguchi, Hitomi,Noiri, Yoshifumi,Iguchi, Naoki,Kameda, Takahiko Korea Institute of Ocean Science Technology 2001 Ocean and Polar Research Vol.23 No.4
Ch1 a abundance, Ch1 a-specific productivity and phytoplankton growth rate in each size fraction (pico, $<2{\mu}m$; nano, $2-10{\mu}m$; micro, > $10{\mu}m$) in the waters around the South Shetland Islands (Ant-arctic Peninsula Area) were analysed. Although Ch1 a-specific productivity and growth rate were highest in micro-size fractions, ChI a abundance was highest in pico-size fractions. Selective removal of nano- and micro-size phytoplankton especially by krill and salp grazing, but not limitation of phytoplankton growth, seemed to be the major reason to explain this miss match between productivity and abundance of the phytoplankton community.